David Hoover elected to Lilly's board of directors
This article was originally published in Scrip
Lilly has appointed David Hoover, chairman, president and CEO of Ball Corporation, as a new member of its board of directors. He will serve under interim election and will stand for election by Lilly shareholders at the company's annual meeting in 2010.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.